VistaPharm®
A PAI PHARMA COMPANY

# REZENOPY™ (Naloxone HCl) Nasal Spray

## 10 mg/0.11 mL




### PRODUCT OVERVIEW:

**REZENOPY™ (naloxone HCl) 10mg/0.11mL, (2) pre-filled, single dose intranasal spray devices per carton**

**NDC:** 83245-003-01

**Indication:** REZENOPY™ (naloxone HCl) 10mg nasal spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients.[1]

## The Highest FDA-Approved Dose Per Nasal Spray for Naloxone in the US Market[2]

**Synthetic opioids like fentanyl — up to 10,000 times more potent than morphine — have fundamentally changed what's required for effective overdose reversal.**

**Highest Dose:** REZENOPY™ delivers 10mg naloxone—the highest FDA-approved dose per nasal spray available. Give your patients the most robust emergency response option when every second counts.

**Treatment Advantages:** Provide maximum naloxone protection in a single easy-to-use device. Caters to the segment of patients who need multiple doses of lower strength for stabilization in emergency situations.

**Broad Coverage:** REZENOPY™, by the virtue of having the maximum amount of naloxone per nasal spray, is designed to improve chances of opioid reversal and provide potential coverage against multiple abuse agents inclusive of synthetic opioids and combinations, in a single dose administration.

| 69,172 | ~816,000 | 10,000x |
|---|---|---|
| Opioid overdose deaths in the past 12 months[3] | People misused Rx fentanyl or iIMF in the past year[4,5] | Fentanyl analogues estimated above the potency of morphine[4,5] |


Contact Your VistaPharm Account Executive  877.530.1633  order@paipharma.com  www.vistapharm.com


[1] REZENOPY™ package insert. On file. | [2] Pharmacokinetic Studies. Data on file. | [3] National Center for Health Statistics, www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
[4] Highlights for the 2024 National Survey on Drug Use and Health, www.SAMHSA.gov | [5] Abdelal et al., Substance Abuse (2022), Vol.43, Issue 1,"The Need for Multiple Naloxone Administrations for Opioid Overdose reversals: A Review of the Literature". | REZENOPY™ and its designs are trademarks of Scienture, LLC, © 2026 VistaPharm, LLC.